Biosig Technologies (NASDAQ:BSGM) is a U.S.-based medical device company that designs and commercializes advanced biomedical signal processing solutions for improving the acquisition, analysis, and interpretation of physiologic signals. Its flagship offering, the PURE EP System, provides real-time noise reduction and signal enhancement during cardiac electrophysiology procedures, enabling physicians to obtain clearer intracardiac electrical readings. This platform is built on proprietary hardware and software algorithms that isolate low-amplitude signals, helping clinicians make more precise diagnoses and treatment decisions.
Founded in 2008 and headquartered in New York, Biosig leverages deep expertise in bioelectronic signal processing to tackle challenges in cardiac catheterization laboratories. The PURE EP System has received 510(k) clearance from the U.S. Food and Drug Administration, and the company is actively pursuing CE marking and other regulatory approvals to expand into European and Asia-Pacific markets. Collaborations with leading academic medical centers and electrophysiology specialists support ongoing clinical evaluations and product refinements.
Beyond electrophysiology, Biosig is exploring broader applications of its signal processing technology in areas such as neuromonitoring and hemodynamic assessment. Its research and development efforts focus on delivering high-fidelity biometric data in real time, with the aim of improving patient outcomes, streamlining clinical workflows, and reducing procedure durations. By leveraging its patented platform, the company seeks to extend its product portfolio to address unmet needs across multiple medical disciplines.
Biosig serves hospitals, ambulatory surgical centers, and research institutions throughout North America and is working to establish a global distribution network through strategic partnerships. The company is guided by a management team with extensive experience in medical technology innovation, clinical research, and commercialization. Biosig’s leadership includes executives who have held senior roles at leading medical device and bioengineering firms, providing a strong foundation for scaling operations and advancing its technology roadmap.
